Topoisomerase 1 inhibition reversibly impairs synaptic function
Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and sy...
Gespeichert in:
| Veröffentlicht in: | Proceedings of the National Academy of Sciences - PNAS 2014-12, Vol.111 (48), p.17290-17295 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 17295 |
|---|---|
| container_issue | 48 |
| container_start_page | 17290 |
| container_title | Proceedings of the National Academy of Sciences - PNAS |
| container_volume | 111 |
| creator | Mabb, Angela M. Kullmann, Paul H. M. Twomey, Margaret A. Miriyala, Jayalakshmi Philpot, Benjamin D. Zylka, Mark J. |
| description | Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and synapse function is currently unknown. Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1 , Neuroligin-1 , Cntnap2 , and GABA Aβ3 . Topotecan also suppressed spontaneous network activity without affecting resting membrane potential, action potential threshold, or neuron health. Topotecan strongly suppressed inhibitory neurotransmission via pre- and postsynaptic mechanisms and reduced excitatory neurotransmission. The effects on synaptic protein levels and inhibitory neurotransmission were fully reversible upon drug washout. Collectively, our findings suggest that TOP1 controls the levels of multiple synaptic proteins and is required for normal excitatory and inhibitory synaptic transmission.
Significance Topoisomerases are enzymes that resolve DNA supercoiling during cell division and gene transcription. Inhibitors of these enzymes are used to treat multiple forms of cancer. Recently we found that topoisomerase inhibitors have profound effects on synaptic genes expressed in the brain. Here we examine the contribution of a clinically used topoisomerase inhibitor on the expression of synaptic proteins and synaptic transmission. We find that inhibition of topoisomerase 1 (TOP1) dampens excitatory and inhibitory synaptic transmission in cortical neurons. Additionally, these effects are fully reversible, because synaptic protein levels and synaptic transmission recover upon washout of the TOP1 inhibitor. These findings provide insights into how inhibition of TOP1 impacts synaptic function in neurons. |
| doi_str_mv | 10.1073/pnas.1413204111 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4260568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>43278653</jstor_id><sourcerecordid>43278653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c558t-d25e8310a91a4d7c2730fbe4a65a65304ee3052c05dc77a4d4cf88bea7351413</originalsourceid><addsrcrecordid>eNqN0cuLFDEQB-Agijuunj2pDV689G5VHp3ksiKLL1jw4HgO6Ux6N0NPp026F-a_N82M4-O0EMihviqo-hHyEuECQbLLcbD5AjkyChwRH5EVgsa64RoekxUAlbXilJ-RZzlvAUALBU_JGRUcOGNqRd6v4xhDjjufbPYVVmG4C22YQhyq5O99yqHt91XYjTakXOX9YMcpuKqbB7eg5-RJZ_vsXxz_c7L-9HF9_aW--fb56_WHm9oJoaZ6Q4VXDMFqtHwjHZUMutZz24jyGHDvGQjqQGyclIVw1ynVeiuZWNY7J1eHsePc7vzG-WFKtjdjCjub9ibaYP6tDOHO3MZ7w2kDolFlwLvjgBR_zj5PZhey831vBx_nbFABAyUEPIA2mmspkLEHUKq1aIA3hb79j27jnIZys6IYV2VRuex5eVAuxZyT704rIpglcbMkbv4kXjpe_32Zk_8dcQHVESydp3GIhiuDkmoo5NWBbPMU08lwRqUq6ZT6m0O9s9HY2xSy-fGdAjYAyHQjNfsFoHnDmQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634873571</pqid></control><display><type>article</type><title>Topoisomerase 1 inhibition reversibly impairs synaptic function</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Mabb, Angela M. ; Kullmann, Paul H. M. ; Twomey, Margaret A. ; Miriyala, Jayalakshmi ; Philpot, Benjamin D. ; Zylka, Mark J.</creator><creatorcontrib>Mabb, Angela M. ; Kullmann, Paul H. M. ; Twomey, Margaret A. ; Miriyala, Jayalakshmi ; Philpot, Benjamin D. ; Zylka, Mark J.</creatorcontrib><description>Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and synapse function is currently unknown. Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1 , Neuroligin-1 , Cntnap2 , and GABA Aβ3 . Topotecan also suppressed spontaneous network activity without affecting resting membrane potential, action potential threshold, or neuron health. Topotecan strongly suppressed inhibitory neurotransmission via pre- and postsynaptic mechanisms and reduced excitatory neurotransmission. The effects on synaptic protein levels and inhibitory neurotransmission were fully reversible upon drug washout. Collectively, our findings suggest that TOP1 controls the levels of multiple synaptic proteins and is required for normal excitatory and inhibitory synaptic transmission.
Significance Topoisomerases are enzymes that resolve DNA supercoiling during cell division and gene transcription. Inhibitors of these enzymes are used to treat multiple forms of cancer. Recently we found that topoisomerase inhibitors have profound effects on synaptic genes expressed in the brain. Here we examine the contribution of a clinically used topoisomerase inhibitor on the expression of synaptic proteins and synaptic transmission. We find that inhibition of topoisomerase 1 (TOP1) dampens excitatory and inhibitory synaptic transmission in cortical neurons. Additionally, these effects are fully reversible, because synaptic protein levels and synaptic transmission recover upon washout of the TOP1 inhibitor. These findings provide insights into how inhibition of TOP1 impacts synaptic function in neurons.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.1413204111</identifier><identifier>PMID: 25404338</identifier><language>eng</language><publisher>United States: National Academy of Sciences</publisher><subject>Action Potentials - drug effects ; Animals ; Autistic disorder ; Biological Sciences ; Brain ; Cancer ; Cell Adhesion Molecules, Neuronal - metabolism ; cell division ; Cells, Cultured ; Cerebral Cortex - cytology ; DNA ; DNA Topoisomerases, Type I - metabolism ; enzymes ; Excitatory Postsynaptic Potentials - drug effects ; Excitatory Postsynaptic Potentials - physiology ; Female ; Gene expression ; Gene expression regulation ; Genes ; Immunoblotting ; Mice, Inbred C57BL ; Microscopy, Fluorescence ; neoplasms ; Neural Cell Adhesion Molecules - metabolism ; Neurons ; Neurons - drug effects ; Neurons - metabolism ; Neurons - physiology ; Neurotransmission ; Neurotransmitters ; Patch-Clamp Techniques ; Proteins ; Receptors ; Synapses ; Synapses - drug effects ; Synapses - physiology ; Synaptic transmission ; Topoisomerase I Inhibitors - pharmacology ; topoisomerase inhibitors ; Topotecan - pharmacology ; transcription (genetics) ; Vehicles</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (48), p.17290-17295</ispartof><rights>copyright © 1993–2008 National Academy of Sciences of the United States of America</rights><rights>Copyright National Academy of Sciences Dec 2, 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c558t-d25e8310a91a4d7c2730fbe4a65a65304ee3052c05dc77a4d4cf88bea7351413</citedby><cites>FETCH-LOGICAL-c558t-d25e8310a91a4d7c2730fbe4a65a65304ee3052c05dc77a4d4cf88bea7351413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/111/48.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/43278653$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/43278653$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27901,27902,53766,53768,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25404338$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mabb, Angela M.</creatorcontrib><creatorcontrib>Kullmann, Paul H. M.</creatorcontrib><creatorcontrib>Twomey, Margaret A.</creatorcontrib><creatorcontrib>Miriyala, Jayalakshmi</creatorcontrib><creatorcontrib>Philpot, Benjamin D.</creatorcontrib><creatorcontrib>Zylka, Mark J.</creatorcontrib><title>Topoisomerase 1 inhibition reversibly impairs synaptic function</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and synapse function is currently unknown. Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1 , Neuroligin-1 , Cntnap2 , and GABA Aβ3 . Topotecan also suppressed spontaneous network activity without affecting resting membrane potential, action potential threshold, or neuron health. Topotecan strongly suppressed inhibitory neurotransmission via pre- and postsynaptic mechanisms and reduced excitatory neurotransmission. The effects on synaptic protein levels and inhibitory neurotransmission were fully reversible upon drug washout. Collectively, our findings suggest that TOP1 controls the levels of multiple synaptic proteins and is required for normal excitatory and inhibitory synaptic transmission.
Significance Topoisomerases are enzymes that resolve DNA supercoiling during cell division and gene transcription. Inhibitors of these enzymes are used to treat multiple forms of cancer. Recently we found that topoisomerase inhibitors have profound effects on synaptic genes expressed in the brain. Here we examine the contribution of a clinically used topoisomerase inhibitor on the expression of synaptic proteins and synaptic transmission. We find that inhibition of topoisomerase 1 (TOP1) dampens excitatory and inhibitory synaptic transmission in cortical neurons. Additionally, these effects are fully reversible, because synaptic protein levels and synaptic transmission recover upon washout of the TOP1 inhibitor. These findings provide insights into how inhibition of TOP1 impacts synaptic function in neurons.</description><subject>Action Potentials - drug effects</subject><subject>Animals</subject><subject>Autistic disorder</subject><subject>Biological Sciences</subject><subject>Brain</subject><subject>Cancer</subject><subject>Cell Adhesion Molecules, Neuronal - metabolism</subject><subject>cell division</subject><subject>Cells, Cultured</subject><subject>Cerebral Cortex - cytology</subject><subject>DNA</subject><subject>DNA Topoisomerases, Type I - metabolism</subject><subject>enzymes</subject><subject>Excitatory Postsynaptic Potentials - drug effects</subject><subject>Excitatory Postsynaptic Potentials - physiology</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene expression regulation</subject><subject>Genes</subject><subject>Immunoblotting</subject><subject>Mice, Inbred C57BL</subject><subject>Microscopy, Fluorescence</subject><subject>neoplasms</subject><subject>Neural Cell Adhesion Molecules - metabolism</subject><subject>Neurons</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neurons - physiology</subject><subject>Neurotransmission</subject><subject>Neurotransmitters</subject><subject>Patch-Clamp Techniques</subject><subject>Proteins</subject><subject>Receptors</subject><subject>Synapses</subject><subject>Synapses - drug effects</subject><subject>Synapses - physiology</subject><subject>Synaptic transmission</subject><subject>Topoisomerase I Inhibitors - pharmacology</subject><subject>topoisomerase inhibitors</subject><subject>Topotecan - pharmacology</subject><subject>transcription (genetics)</subject><subject>Vehicles</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0cuLFDEQB-Agijuunj2pDV689G5VHp3ksiKLL1jw4HgO6Ux6N0NPp026F-a_N82M4-O0EMihviqo-hHyEuECQbLLcbD5AjkyChwRH5EVgsa64RoekxUAlbXilJ-RZzlvAUALBU_JGRUcOGNqRd6v4xhDjjufbPYVVmG4C22YQhyq5O99yqHt91XYjTakXOX9YMcpuKqbB7eg5-RJZ_vsXxz_c7L-9HF9_aW--fb56_WHm9oJoaZ6Q4VXDMFqtHwjHZUMutZz24jyGHDvGQjqQGyclIVw1ynVeiuZWNY7J1eHsePc7vzG-WFKtjdjCjub9ibaYP6tDOHO3MZ7w2kDolFlwLvjgBR_zj5PZhey831vBx_nbFABAyUEPIA2mmspkLEHUKq1aIA3hb79j27jnIZys6IYV2VRuex5eVAuxZyT704rIpglcbMkbv4kXjpe_32Zk_8dcQHVESydp3GIhiuDkmoo5NWBbPMU08lwRqUq6ZT6m0O9s9HY2xSy-fGdAjYAyHQjNfsFoHnDmQ</recordid><startdate>20141202</startdate><enddate>20141202</enddate><creator>Mabb, Angela M.</creator><creator>Kullmann, Paul H. M.</creator><creator>Twomey, Margaret A.</creator><creator>Miriyala, Jayalakshmi</creator><creator>Philpot, Benjamin D.</creator><creator>Zylka, Mark J.</creator><general>National Academy of Sciences</general><general>National Acad Sciences</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20141202</creationdate><title>Topoisomerase 1 inhibition reversibly impairs synaptic function</title><author>Mabb, Angela M. ; Kullmann, Paul H. M. ; Twomey, Margaret A. ; Miriyala, Jayalakshmi ; Philpot, Benjamin D. ; Zylka, Mark J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c558t-d25e8310a91a4d7c2730fbe4a65a65304ee3052c05dc77a4d4cf88bea7351413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Action Potentials - drug effects</topic><topic>Animals</topic><topic>Autistic disorder</topic><topic>Biological Sciences</topic><topic>Brain</topic><topic>Cancer</topic><topic>Cell Adhesion Molecules, Neuronal - metabolism</topic><topic>cell division</topic><topic>Cells, Cultured</topic><topic>Cerebral Cortex - cytology</topic><topic>DNA</topic><topic>DNA Topoisomerases, Type I - metabolism</topic><topic>enzymes</topic><topic>Excitatory Postsynaptic Potentials - drug effects</topic><topic>Excitatory Postsynaptic Potentials - physiology</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene expression regulation</topic><topic>Genes</topic><topic>Immunoblotting</topic><topic>Mice, Inbred C57BL</topic><topic>Microscopy, Fluorescence</topic><topic>neoplasms</topic><topic>Neural Cell Adhesion Molecules - metabolism</topic><topic>Neurons</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neurons - physiology</topic><topic>Neurotransmission</topic><topic>Neurotransmitters</topic><topic>Patch-Clamp Techniques</topic><topic>Proteins</topic><topic>Receptors</topic><topic>Synapses</topic><topic>Synapses - drug effects</topic><topic>Synapses - physiology</topic><topic>Synaptic transmission</topic><topic>Topoisomerase I Inhibitors - pharmacology</topic><topic>topoisomerase inhibitors</topic><topic>Topotecan - pharmacology</topic><topic>transcription (genetics)</topic><topic>Vehicles</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mabb, Angela M.</creatorcontrib><creatorcontrib>Kullmann, Paul H. M.</creatorcontrib><creatorcontrib>Twomey, Margaret A.</creatorcontrib><creatorcontrib>Miriyala, Jayalakshmi</creatorcontrib><creatorcontrib>Philpot, Benjamin D.</creatorcontrib><creatorcontrib>Zylka, Mark J.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mabb, Angela M.</au><au>Kullmann, Paul H. M.</au><au>Twomey, Margaret A.</au><au>Miriyala, Jayalakshmi</au><au>Philpot, Benjamin D.</au><au>Zylka, Mark J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Topoisomerase 1 inhibition reversibly impairs synaptic function</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>2014-12-02</date><risdate>2014</risdate><volume>111</volume><issue>48</issue><spage>17290</spage><epage>17295</epage><pages>17290-17295</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>Topotecan is a topoisomerase 1 (TOP1) inhibitor that is used to treat various forms of cancer. We recently found that topotecan reduces the expression of multiple long genes, including many neuronal genes linked to synapses and autism. However, whether topotecan alters synaptic protein levels and synapse function is currently unknown. Here we report that in primary cortical neurons, topotecan depleted synaptic proteins that are encoded by extremely long genes, including Neurexin-1 , Neuroligin-1 , Cntnap2 , and GABA Aβ3 . Topotecan also suppressed spontaneous network activity without affecting resting membrane potential, action potential threshold, or neuron health. Topotecan strongly suppressed inhibitory neurotransmission via pre- and postsynaptic mechanisms and reduced excitatory neurotransmission. The effects on synaptic protein levels and inhibitory neurotransmission were fully reversible upon drug washout. Collectively, our findings suggest that TOP1 controls the levels of multiple synaptic proteins and is required for normal excitatory and inhibitory synaptic transmission.
Significance Topoisomerases are enzymes that resolve DNA supercoiling during cell division and gene transcription. Inhibitors of these enzymes are used to treat multiple forms of cancer. Recently we found that topoisomerase inhibitors have profound effects on synaptic genes expressed in the brain. Here we examine the contribution of a clinically used topoisomerase inhibitor on the expression of synaptic proteins and synaptic transmission. We find that inhibition of topoisomerase 1 (TOP1) dampens excitatory and inhibitory synaptic transmission in cortical neurons. Additionally, these effects are fully reversible, because synaptic protein levels and synaptic transmission recover upon washout of the TOP1 inhibitor. These findings provide insights into how inhibition of TOP1 impacts synaptic function in neurons.</abstract><cop>United States</cop><pub>National Academy of Sciences</pub><pmid>25404338</pmid><doi>10.1073/pnas.1413204111</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8424 |
| ispartof | Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (48), p.17290-17295 |
| issn | 0027-8424 1091-6490 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4260568 |
| source | Jstor Complete Legacy; MEDLINE; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Action Potentials - drug effects Animals Autistic disorder Biological Sciences Brain Cancer Cell Adhesion Molecules, Neuronal - metabolism cell division Cells, Cultured Cerebral Cortex - cytology DNA DNA Topoisomerases, Type I - metabolism enzymes Excitatory Postsynaptic Potentials - drug effects Excitatory Postsynaptic Potentials - physiology Female Gene expression Gene expression regulation Genes Immunoblotting Mice, Inbred C57BL Microscopy, Fluorescence neoplasms Neural Cell Adhesion Molecules - metabolism Neurons Neurons - drug effects Neurons - metabolism Neurons - physiology Neurotransmission Neurotransmitters Patch-Clamp Techniques Proteins Receptors Synapses Synapses - drug effects Synapses - physiology Synaptic transmission Topoisomerase I Inhibitors - pharmacology topoisomerase inhibitors Topotecan - pharmacology transcription (genetics) Vehicles |
| title | Topoisomerase 1 inhibition reversibly impairs synaptic function |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T14%3A02%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Topoisomerase%201%20inhibition%20reversibly%20impairs%20synaptic%20function&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Mabb,%20Angela%20M.&rft.date=2014-12-02&rft.volume=111&rft.issue=48&rft.spage=17290&rft.epage=17295&rft.pages=17290-17295&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.1413204111&rft_dat=%3Cjstor_pubme%3E43278653%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1634873571&rft_id=info:pmid/25404338&rft_jstor_id=43278653&rfr_iscdi=true |